## Mathematical modeling and analysis of tumor-immune interactions

### Kevin Atsou<sup>1</sup> Thierry Goudon<sup>1</sup> Biologists : Véronique Braud<sup>2</sup> Fabienne Anjuere<sup>2</sup>

<sup>1</sup>Université Côte d'Azur, Inria (Team COFFEE), CNRS, LJAD

<sup>2</sup>CNRS, IPMC (Institut de Pharmacologie Moléculaire et Cellulaire)

6 août 2019









Atsou, Goudon

#### 1 tumors and effector T-cells interactions : Biological context

### 2 Mathematical modeling : Earlier stages of tumor-growth

One state in the state of th

The Immune system

## Summary



2 Mathematical modeling : Earlier stages of tumor-growth

3 Numerical simulations

The Immune system

## The Immune system Attacks Tumor cells

- Immunotherapy starts in 1891 with W. Coley (Coley's toxins);
- Immunotherapy restarted seriously With the appearance of AIDS;
- immunodeficient patients often develop cancer

source : https ://gifer.com/en/7ftZ

• Immune cells play an important role in the control or in the development of tumors 1

The Immune system

## Two types of Immune system



Atsou, Goudon

The Immune system

## Tumor cells cycle

• Genes involved in cell cycle control are subject to the genetic alterations  $\implies$  cancer  $\implies$  Uncontrolled Cell division



3

<sup>3.</sup> source : https ://curioussciencewriters.org/

The Immune system

## Tumor Immunity Cycle

#### The Cancer-Immunity Cycle



4. source : http://biocc.hrbmu.edu.cn/TIP/

Atsou, Goudon

## K.Atsou - Impediments of the tumor immunity cycle

#### Tumor has many suppressive influences

The prevalence of cancer indicates that the immune system does not have a strong enough effect on Tumors.

- high levels of suppressive cytokines;
- **T** regulatory cells (Tregs produce TGF- $\beta$  and IL-10);
- high expression of PD-L1 (Programmed death-ligand 1) by tumors;
- Production of VEGF (Vascular Endothelial Growth Factor) for angiogenesis;





2 Mathematical modeling : Earlier stages of tumor-growth

3 Numerical simulations

## A growth-fragmentation modeling approach : Tumor

- $(t,z) \mapsto n(t,z)$  (in  $cell_n \cdot \mu m^{-3}$ ) the size-structured tumor cells distribution
- $(t, x) \mapsto c(t, x)$  (in  $cell_c \cdot mm^{-3}$ ) the concentration of Effector T cells

## Tumor growth main processes

Tumor growth is splitted into two main processes :

- natural (microscopic) growth of the cells,
- cell division.

5

. source : https ://gifer.com/en/9uMp

## A growth-fragmentation modeling approach : Tumor

We model the tumor growth by the following equation :

$$\frac{\partial}{\partial t}n(t,z) = \underbrace{-\frac{\partial}{\partial z}(V(z)n(t,z))}_{\text{the cell's volume growth}} + \underbrace{\frac{Q(n(t,z))}_{\text{Cellular division operator}}.$$

We can complete the equation by the initial data,

$$n(t=0,z)=n_0$$

and the boundary condition,

$$n(t,0)=0$$

## The cellular division

$$\frac{\partial}{\partial t}n(t,z) = \underbrace{-\frac{\partial}{\partial z}(V(z)n(t,z))}_{\text{the cell's volume growth}} + \underbrace{Q(n(t,z))}_{\text{Cellular division operator}}.$$

Q(n(t,z))?

- a(z), the rate at which cells of size z process division.
- k(z'|z) the distribution of products from a cells of size z dividing.

## The cellular division

k(z'|z) must be normalized so that mass is conserved :

$$\int_0^z z' k(z'|z) dz' = z.$$
(1)

Consequently,

$$Q(n) = \underbrace{-a(z)n(t,z)}_{\text{The loss of cells of size } z} + \underbrace{\int_{z}^{\infty} a(z')k(z|z')n(t,z')dz'}_{\text{gain of cells with size } z}.$$
 (2)

## Binary and symmetric The cellular division

$$Q(n) = \underbrace{-a(z)n(t,z)}_{\text{The loss of cells of size } z} + \underbrace{\int_{z}^{\infty} a(z')k(z|z')n(t,z')dz'}_{\text{gain of cells with size } z}.$$
 (3)

We assume binary and symmetric division process. Therefore cells of size 2z give birth to cells of size z.  $k(z|2z) = 2\delta_{z'=2z}$ 

$$Q(n(t,z)) = -a(z)n(t,z) + 2a(2z)n(t,2z)d(2z)$$
(4)

$$Q(n(t, z)) = \underbrace{4a(2z)n(t, 2z)}_{\text{gain of cells with size } z} - \underbrace{a(z)n(t, z)}_{\text{The loss of cells of size } z}$$
(5)

#### **Chemotaxis phenomenon**



**T** cells displacement towards the tumor microenvironment is model by chemotaxis.

## K.A - The antigen-specific CD8+ effector T cells displacement

the activated T cells follows the gradient of the chemical signal

# K.A - The antigen-specific CD8+ effector T cells displacement

the activated T cells follows the gradient of the chemical signal

Let's denote by

$$\Omega = \{ \mathbf{x} \in \mathbb{R}^N, |\mathbf{x}| \le R \},\$$

 $c_{\omega}(t)$  the time dependent concentration of immune cells in a volume  $\omega \subset \Omega$  :

$$c_{\omega}(t) = \int_{\omega} c(t, x) dx$$
 (6)



## The tumor mass : kth order moments

Let's denote by μ<sub>0</sub>(t) (the zeroth order moment) the total number of tumor cells in the tumor;

$$\mu_0(t) = \int_0^\infty n(t, z) dz \tag{7}$$

Let's denote by µ<sub>1</sub>(t) (the first order moment) the total volume of the tumor;

$$\mu_1(t) = \int_0^\infty z n(t, z) dz \tag{8}$$

## The Chemotaxis model

$$\frac{\partial c}{\partial t}(t,x) + \overbrace{\nabla \cdot (\chi_{\Phi}(\nabla_{x}\Phi)c)}^{\text{Convection term}} - \overbrace{D(\nabla_{x}c)}^{\text{Diffusion term}} = \overbrace{\rho_{f}g(\mu_{1})S}^{\text{Conversion of Im. cells}} - \overbrace{\gamma c}^{\text{Natural Death}} (9)$$

Typical conversion law of Naive T cells (Saturated conversion).

$$g(\mu_1) = \frac{\mu_1}{\delta + \mu_1} \tag{10}$$

## Tumor antigen-induced potential

#### The attractive potential $\Phi$ satisfies a Poisson equation :

$$-\nabla \cdot (k(x)\nabla\Phi) = \langle \sigma \rangle \int_0^\infty zn(t,z) dz,$$
  
$$-\nabla \cdot (k(x)\nabla\Phi) = \mu_1(t) \langle \sigma \rangle,$$
  
With Neumann homogeneous boundary condition.

$$\mathbf{k}(\mathbf{x})\nabla_{\mathbf{x}}\Phi(\mathbf{x})\cdot\mathbf{n}_{\partial\Omega}=0$$

where  $\langle \sigma \rangle = \sigma - \frac{1}{|\Omega|} \int_{\Omega} \sigma \, \mathrm{d}x$ 

## A chemotaxis model : Immune cells

#### The resulting Chemotaxis model

$$\begin{cases} \partial_t c(t,x) + \nabla \cdot (\chi(\phi)(\nabla_x \phi)c - (D(x)\nabla_x c)) = pg(\mu_1)S - \gamma c, & \forall t > 0, x \in \Omega \\ -\nabla \cdot (k(x)\nabla\phi) = \int_0^\infty zn(t,z)\sigma(x,z)dz, & \forall t, z > 0, x \in \Omega \\ c = 0, & \forall x \in \partial\Omega, \\ c(t = 0, x) = c_0(x), & \forall x \in \Omega, \\ k(x)\nabla\phi \cdot n_{\partial\Omega} = 0 & \forall x \in \partial\Omega. \end{cases}$$

## Tumor vs Immune cells : the interactions term

Let's denote by m(c, n) the death term describing the immune response The tumor growth model becomes :

$$\frac{\partial}{\partial t}n(t,z) = -\frac{\partial}{\partial z}(Vn(t,z)) + Q(n(t,z)) - \underbrace{m(c,n)}_{m(c,n)}$$

The interaction Tumor-Im. Cells

## Tumor vs Immune cells : the interactions term

Let's denote by m(c, n) the death term describing the immune response The tumor growth model becomes :

$$\frac{\partial}{\partial t}n(t,z) = -\frac{\partial}{\partial z}(Vn(t,z)) + Q(n(t,z)) - \underbrace{m(c,n)}_{\text{The interaction Tumor Im}} Q(t,z) - \underbrace{m(c,n)}_{\text{The interaction Tumor Im}} Q(t,z) + Q(t,z)$$

The interaction Tumor-Im. Cells

$$m(c,n)(t) = \int_{\Omega} \delta(y)c(t,y)dy \times \frac{n(t,z)}{\alpha + n(t,z)}.$$

#### where $\delta$ is an interaction kernel

## Asymptotic behavior : Tumor growth

We turn back to the tumor growth equation without immune response :

$$\begin{cases} \partial_t n(t,z) = -\partial_z (V(z)n(t,z)) - a(z)n(t,z) + 4a(z)n(t,2z), & \forall (t,z) \in \mathbb{R}_+^* \times \mathbb{R}_+\\ n(t,0) = 0, & \forall t \ge 0,\\ n(t=0,z) = n_0(z) \in L^1(\mathbb{R}_+), & \forall z \ge 0, \end{cases}$$

The solution behaves like :  $(t, z) \mapsto \rho e^{\lambda t} N(z)$  with  $\rho = \int_{\mathbb{R}_+} n_0(z)$ 

## Asymptotic behavior : Tumor growth

The long time behavior of *n* is directly linked with the existence of a solution  $\lambda$ , *N*,  $\phi$ , in  $L^1$  sense, of the associated eigenproblem,

$$\begin{cases} \partial_z (V(z)N(z)) + (\lambda + a(z))N(z) = 4a(z)N(2z), \quad z \ge 0\\ N(0) = 0, \quad N(z) > 0 \text{ for } z > 0, \quad \int_0^\infty N(Z)dz = 1\\ V(z)\partial_z \psi(z) - (\lambda + a(z))\psi(z) = -2a(z)\psi(\frac{z}{2}), \quad x \ge 0\\ \psi(z) > 0 \text{ for } x \ge 0, \int_0^\infty N(z)\psi(z)dz = 1 \end{cases}$$

## Asymptotic behavior : Tumor growth

The solution of the dual equation allows to define a conservation law on n(t, z):

Mass Conservation

$$\int_0^\infty n(t,z)e^{-\lambda t}\psi(z)dz = \int_0^\infty n_0(z)\psi(z)dz$$

## Existence and uniqueness of the eigenelements

#### Theorem, B. Perthame et al., 2005

if the division rate *a* is lower bounded and upper bounded, then there is a unique solution  $(\lambda, N, \psi)$  to the eigenproblem with  $\psi$ , *N* in  $C^1(\mathbb{R}_+)$  and moreover, all the moments of the asymptotic state *N* are bounded.

The existence of the eigenelements is based on the **Krein-Rutman Theorem** 

## Asymptotic behavior : Tumor growth

Exponential decay to the leading eigenpair of the growth-fragmentation operator :

#### Theorem, B. Perthame et al., 2004

If the division rate and the growth rate of the tumor are constant, there is a unique solution to the first eigenvalue problem. This solution belongs to the Schwartz space and furthermore, all the solutions to the tumor growth equation converges exponentially to the first eigenvector with a rate equal to the tumor division rate.

## Asymptotic behavior : Tumor growth

There is a semi-explicit formula for the leading eigenfunction N (F. Baccelli, 2002, B. Perthame et al., 2004 ) given by a series that **converges absolutely and uniformly** 

#### Lemma, F.Baccelli, 2002

Let 
$$\alpha_0 = 1$$
,  $\alpha_n = \frac{2}{2^n - 1} \alpha_{n-1}$ , then the function

$$N(z) = \langle N \rangle \sum_{n=0}^{\infty} (-1)^n \alpha_n \exp\left(-2^{n+1} \frac{a}{V} z\right),$$

belongs to  $\mathcal{S}(\mathbb{R}^+)$  and is unique.

different profiles :

## Asymptotic behavior : Tumor growth



#### An example of time evolution :



## Asymptotic behavior : Tumor growth

#### Existence and uniqueness of eigenelements has been proved

#### Residual distribution

- the system reaches a certain **equilibrium state**, with a non zero tumor cells distribution
- In which cases the immune system can control the tumor progression?

## Asymptotic behavior : Immune cells taking control

An attempt which clarifies this issue is provided by the following statement for small division rates (non-aggressive tumors)

#### Proposition, Kevin ATSOU & Thierry Goudon

If the tumor is **non-aggressive**, there exist a **unique tumor mass** which depends on the tumor division rate at which the tumor is always **controlled by the immune cells**.





2 Mathematical modeling : Earlier stages of tumor-growth

Output: Second State State

### model parameters

#### • Variable parameters :



## Homogeneous distribution of Naive cells : a = 1

Tumor vs Homogeneous distribution of Immune cells :

### Homogeneous distribution of Naive cells : a



FIGURE – behavior of the solutions. ( $\mu_1$  in red,  $\mu_c$  in blue, *a* in black)

Atsou, Goudon

athematical modeling and analysis of tumor-imi

## Heterogeneous distribution of Naive cells

Tumor vs Heterogeneous distribution of Immune cells :



## Heterogeneous distribution of Naive cells : a = 4

Tumor vs Heterogeneous distribution of Immune cells :

## Heterogeneous distribution of Naive cells



FIGURE – Evolution of the tumor mass  $\mu_1$  (red curves, left axis), and of

Atsou, Goudon

lathematical modeling and analysis of tumor-im

#### Thank you for your attention...

39